Market evolution: Pharmaceutical products (CN 30) — 2015–2025

Introduction

This report examines the evolution of the European Union's external trade in pharmaceutical products (customs code CN 30) over the period 2015–2025. The CN 30 heading encompasses a broad range of products, from medicaments in measured doses (CN 3004) and vaccines and blood-derived products (CN 3002) to surgical dressings (CN 3005) and pharmaceutical preparations (CN 3006). Over the decade, the EU pharmaceutical trade balance widened dramatically, underpinned by surging export values and a persistent structural surplus. Three principal dynamics stand out: the EU's consolidation as a pharmaceutical export powerhouse driven by price escalation rather than volume growth; a profound reorientation of bilateral trade partners shaped by geopolitical shocks such as Brexit and the COVID-19 pandemic; and growing intra-EU specialization that concentrates production in a handful of member states while increasing the bloc's overall trade exposure.

1. Export-driven value explosion: the EU's widening pharmaceutical surplus

The trade balance more than doubled despite sluggish volume growth

Between 2015 and 2025, the EU's pharmaceutical trade balance with non-EU countries grew from €72.4 billion to €189.7 billion, an increase of 162.0%. This expansion was overwhelmingly driven by exports, whose total value rose from €139.7 billion to €306.9 billion (+119.8%), while imports grew more modestly from €67.2 billion to €117.2 billion (+74.4%). Crucially, the physical volume of exports increased by only 18.3% (from 1,142,068 to 1,350,664 tonnes), whereas export prices surged by 85.9% (from €122,278 to €227,254 per tonne). On the import side, volumes actually declined by 9.5% (from 523,207 to 473,640 tonnes), while import prices rose by 92.6%.

Price escalation, not volume, was the main engine of value growth

The dominant feature of the decade is a broad price appreciation across pharmaceutical products. Both export and import unit values roughly doubled, while quantities moved only modestly. This pattern is consistent with a global pharmaceutical market increasingly driven by high-value biologics, immunological products, and specialty medicines, which command substantially higher per-kilogram prices than traditional small-molecule drugs. The EU's net import reliance shifted from −25.2% to −439.4%, reflecting the fact that the bloc's export surplus expanded far faster than its domestic production base, raising the EU's effective export propensity from 37.7% to 128.6%.

Biologics and blood-derived products (CN 3002) became the highest-value segment

The product segment breakdown reveals that CN 3002 — covering antisera, blood fractions, immunological products, vaccines, and cell cultures — underwent the most dramatic value transformation. On the export side, CN 3002's value grew from €33.2 billion in 2015 to €114.9 billion in 2025, nearly overtaking the traditionally dominant CN 3004 (medicaments in doses). Meanwhile, CN 3002 export unit prices more than doubled, from €632,468/t to €1,385,662/t, confirming a structural shift toward higher-value biologics.

EU production grew in value but lagged behind trade

The EU's pharmaceutical production value increased from €31.8 billion to €219.6 billion (+590.4%), while production volume grew from 50 million items to 84.9 million items (+69.7%). The outsized value growth relative to volume mirrors the same price-escalation dynamic observed in trade data and suggests that EU manufacturers have moved decisively up the value chain, producing fewer physical units but of substantially higher value.

2. Geopolitical realignment: shifting partners and growing concentration

The United States became the EU's dominant pharmaceutical trade partner

The most consequential geographic shift in the decade was the deepening of EU-US pharmaceutical trade. EU exports to the United States surged from €37.0 billion to €108.6 billion (+193.7%), making the US by far the largest single destination for EU pharmaceuticals in 2025, absorbing over one-third of all extra-EU pharmaceutical exports. On the import side, the US remained the largest supplier, with imports rising from €25.6 billion to €43.6 billion (+70.7%). This asymmetric growth — exports nearly tripling while imports increased by 71% — transformed the bilateral balance in the EU's favor and cemented the US as the linchpin of the EU's pharmaceutical trade surplus.

Switzerland transitioned from a balanced partner to a major export destination

EU exports to Switzerland grew from €12.5 billion to €59.2 billion (+372.7%), the fastest expansion among the top seven partners. Imports from Switzerland also grew significantly, from €15.8 billion to €39.1 billion (+146.8%), but the balance shifted dramatically. In 2015, the EU ran a small deficit with Switzerland in pharmaceuticals; by 2025, it was running a surplus of approximately €20.2 billion. This likely reflects the relocation of pharmaceutical production and distribution activities, as well as Switzerland's role as a staging ground for re-exports.

Brexit reshaped EU-UK pharmaceutical flows

The United Kingdom, historically one of the EU's most important pharmaceutical partners, saw a decline in its relative position. EU imports from the UK fell from €12.4 billion to €9.0 billion (−27.3%), while exports to the UK declined from €22.3 billion to €20.4 billion (−8.5%). The UK's departure from the EU single market and customs union introduced new regulatory barriers that partially disrupted supply chains. Nevertheless, the UK remained the EU's largest single-country import source by volume-adjacent metrics, suggesting persistent structural ties in pharmaceutical manufacturing.

Emerging partners — China, India, and Serbia — gained ground rapidly

Several non-traditional partners experienced outsized growth. EU imports from China surged by 418.7% (from €1.0 billion to €5.4 billion), and from India by 238.5% (from €0.9 billion to €2.9 billion), reflecting the growing role of Asian manufacturers in active pharmaceutical ingredient (API) production and generic drug supply. Serbia (+258.2%) emerged as a small but fast-growing source, likely benefiting from its EU candidacy status and proximity. EU export volatility toward Russia was notably high, with a coefficient of variation of 1.45 on imports, reflecting the uncertainty introduced by sanctions and geopolitical tensions since 2022.

Trade concentration intensified on both sides

The Herfindahl-Hirschman Index (HHI) for export value rose from 1,192 to 1,876 (+57.4%), indicating that EU pharmaceutical exports became substantially more concentrated among a smaller set of destination countries — primarily the US and Switzerland. Import concentration also edged up, from 2,448 to 2,695 (+10.1%), remaining at a level that suggests moderate concentration among a few dominant suppliers. The rising export HHI is a risk factor: should trade relations with the US or Switzerland deteriorate, the EU would face outsized exposure.

3. Specialization, capacity gaps, and the COVID-19 inflection

A handful of member states drive the EU's pharmaceutical export capacity

The EU's specialization profile in 2025 reveals extreme intra-bloc concentration. Ireland leads with an RSCA of 0.7541 (RCA of 7.13), reflecting its role as the home of major multinational pharmaceutical manufacturers. Belgium (RSCA 0.176) and Italy (RSCA 0.172) are moderately specialized. By contrast, several member states — notably Estonia (RSCA −0.774), Slovakia (−0.754), Romania (−0.587), and Poland (−0.560) — exhibit significant negative specialization, meaning their pharmaceutical exports are far below what their overall trade profile would predict.

The EU's top importing member states are concentrated in Western Europe

On the import side, Belgium (€23.7 billion), Germany (€21.0 billion), the Netherlands (€16.0 billion), and France (€8.6 billion) dominated in 2025. Ireland, notably, saw its pharmaceutical imports grow by 164.1% (from €3.2 billion to €8.3 billion), likely reflecting the expansion of biopharmaceutical manufacturing hubs that rely on imported raw materials and intermediates. The export leadership was dominated by Germany (€66.9 billion), Belgium (€38.0 billion), Ireland (€42.2 billion), and the Netherlands (€27.7 billion). Italy's exports grew by an extraordinary 416.5% (from €6.8 billion to €35.1 billion), propelling it into the top tier.

The COVID-19 pandemic produced a dramatic but temporary spike in CN 3002

The import data for CN 3002 — which includes vaccines and immunological products — shows a clear pandemic inflection. Import volumes surged from 51,108 tonnes in 2020 to 122,707 tonnes in 2021, driven by the mass importation of COVID-19 vaccines and related biologics. By 2022, volumes had normalized to 53,162 tonnes, and the 2025 figure stands at 47,375 tonnes. On the export side, CN 3002 values peaked in 2022 at €108.8 billion before moderating to €114.9 billion in 2025, with the apparent paradox of rising value despite lower peak volumes explained by the persistent high unit prices of biologic products (€1,385,662/t in 2025 vs. €632,468/t in 2015).

Price shocks were detected in smaller but strategically significant markets

The volatility analysis identified notable export price shocks to Israel (2021, +55.5% shift with 273.6 abnormality), Serbia (2018, +85.0%), and the United Arab Emirates (2021, +35.5%). While these shocks affected small shares of total EU pharmaceutical exports (0.4–0.8%), they illustrate the price sensitivity of pharmaceutical trade to regulatory changes, emergency procurement, and market-specific disruptions. On the import side, trade with Russia exhibited by far the highest volatility (CV of 1.45), reflecting the impact of geopolitical sanctions and supply chain disruptions.

Conclusion

The EU's pharmaceutical trade with non-EU countries between 2015 and 2025 was characterized by three reinforcing trends: a value explosion driven primarily by price appreciation rather than volume expansion; a decisive geographic reorientation toward the United States and Switzerland and away from the United Kingdom; and increasing intra-EU specialization that concentrates production capacity in Ireland, Germany, Belgium, Italy, and the Netherlands. The COVID-19 pandemic left a visible but transient mark on the CN 3002 segment, while the underlying structural shift toward high-value biologics continued unabated. The EU's pharmaceutical trade surplus more than doubled to nearly €190 billion, but the growing concentration of export destinations — reflected in the rising HHI — introduces a vulnerability that policymakers should monitor. Overall, the data paint a picture of an EU pharmaceutical sector that has successfully upgraded its product mix and expanded its global market share, even as the geographic and structural foundations of that success have become more concentrated and, potentially, more fragile.